Prostate cancer survivors benefit from non-vigorous activity, walking
the ONA take:
After prostate cancer diagnosis, at least five hours of non-vigorous activity or 3 hours of walking is positively associated with better hormone and vitality functioning, according to a study published in the Journal of Cancer Survivorship.
Siobhan Phillips, PhD, MPH, at Northwestern University Feinberg School of Medicine and fellow researchers prospectively examined 1,917 men diagnosed with non-metastatic prostate cancer in the Health Professionals Follow-Up Study.
They looked at associations between activity and sedentary behavior after prostate cancer diagnosis in terms of health-related quality of life.
The researchers found that, upon adjusting for confounders, higher duration of non-vigorous and walking activity were associated with higher vitality and hormonal functioning scores.
The effects approached clinical significance for men in the highest versus lowest categories, with survivors who walked at least 90 minutes a week at a normal or faster pace reporting higher scores than men who walked less than 90 minutes a week at an easy pace.
Total activity was found to be associated with higher hormone and vitality functioning in men who were at least five years post-treatment and had more advanced disease.
“Encouraging men to engage in non-vigorous activity and walking may be helpful for managing prostate cancer-related health-related quality of life,” the authors concluded.
After prostate cancer diagnosis, at least five hours of non-vigorous activity or 3 hours of walking is beneficial.
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Endocrine Society Released Guidelines for Managing Endocrine Disorders in Childhood Cancer Survivors
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|